Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,044 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Urologic Diseases Clear all

Conditions: Urolithiasis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 0 Years to 18 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 31
States / cities: Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more

Conditions: Glomerulonephritis
Interventions: LNP023; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions: INCB001158, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 13
States / cities: Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more

Conditions: Stress Urinary Incontinence
Interventions: Vesair Balloon; Device
Lead sponsor: Solace Therapeutics, Inc.; Industry
Eligibility: Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 8
States / cities: Arlington Heights, Illinois • Shreveport, Louisiana • Hanover, Maryland + 5 more

Conditions: Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI, Recurrent C. Diff, rCDI, C. Difficile, Recurrent CDI, FMT, Fecal Microbiota, Fecal Transplant
Interventions: CP101; Biological
Lead sponsor: Finch Research and Development LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Scottsdale, Arizona • Los Angeles, California • Murrieta, California + 47 more

Conditions: Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Interventions: Selenomethionine (SLM), Axitinib; Drug
Lead sponsor: Mohammed Milhem; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Renal Tumor, Renal Cell Carcinoma, Renal Tumor, Benign
Interventions: 2-Deoxy-2-[18F]fluoroglucose Positron Emission Tomography/Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Houston, Texas

Conditions: End-Stage Renal Disease (ESRD)
Interventions: EPN-701 (Oral); Drug
Lead sponsor: Epizon Pharma, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Kidney Disease
Interventions: Propranolol, Losartan, Eprosartan; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Urinary Tract Infections
Interventions: Urine PCR testing; Diagnostic Test
Lead sponsor: David Sheyn; Other
Eligibility: 60 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Urethral Obstruction
Interventions: Fetal Intervention for LUTO; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 11 Weeks to 2 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pelvic Organ Prolapse, Stress Urinary Incontinence, Overactive Bladder
Interventions: Pelvic organ prolapse decision aid, Stress urinary incontinence decision aid, Overactive bladder decision aid; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Pazopanib, Sorafenib, Radium-223; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Nosocomial Infection, Bacteremia, Sepsis, Pneumonia, Urinary Tract Infection, Clostridium Infection
Interventions: 2% chlorhexidine gluconate impregnated cloth, Daily bathing with Bar soap; Drug · Other
Lead sponsor: Cook County Health; Government
Eligibility: 16 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
Interventions: Transcutaneous auricular vagus nerve stimulation, Sham device; Device
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Hyde Park, New York • Philadelphia, Pennsylvania

Conditions: End-Stage Renal Disease
Interventions: exposure to a high-calcium dialysate bath; Procedure
Lead sponsor: James B. Wetmore, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Bladder Cancer, High Grade, Non Muscle Invasive
Interventions: oncolytic adenovirus expressing GMCSF; Biological
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Bladder Cancer, Ta/T1, CIS
Interventions: nadofaragene firadenovec; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Little Rock, Arkansas • Atlanta, Georgia

Conditions: Bladder Cancer
Interventions: questionnaires, Saliva and/or urine sample; Behavioral · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 4
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 1 more

Conditions: Pyelonephritis, Pyelonephritis Acute, Renal Sclerosis
Interventions: Quick MRI; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 0 Years to 21 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: End Stage Renal Disease
Interventions: Relaxation and guided imagery program; Behavioral
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Head and Neck Cancer, Colorectal Cancer
Interventions: PF-07921585, Sasanlimab; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 4 more

Conditions: Type 2 Diabetes (T2DM), Geriatric Syndromes, Disability Hearing, Disability Physical, Urinary Tract Infection(UTI), Delirium Confusional State
Interventions: Cinematic Virtual Reality Training, Traditional Didactic Lecture; Behavioral
Lead sponsor: Ohio University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Athens, Ohio

Search by objective public record fields.

Radiation Dose of Pediatric Patients During Ureteroscopy

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Vesair Balloon Confirmatory Trial (VECTOR)

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection

SLM + Axitinib for Clear Cell RCC

PET/MR for Characterization of Renal Masses (RMs)

A Clinical Trial of Epizon-701 (EPN-701) in Subjects With End-Stage Renal Disease (ESRD)

Pharmacokinetic Study in Patients With Chronic Kidney Disease and Healthy Volunteers

Urine Gene Analysis for Pathogen Detection

Standardized Prenatal Clinical Care for LUTO

Impact of Decision Aids in Urogynecology

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Skin Cleansing With Chlorhexidine to Decrease Hospital Acquired Infections

taVNS for FRNS in Children

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Determinants of Bladder Cancer Recurrence Study (The DETER Study)

The Validity of the Quick Renal MRI in Pediatric Kidney Disease

A Guided Meditation Program in Patients Undergoing Dialysis

A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer

Using Virtual Reality to Improve Medical Training